Solid Biosciences LLC

SLDB.US
Healthcare · Biotechnology
7.97
+0.08 (+1.01%)
USD · NASDAQ

Company Information

Company Name
Solid Biosciences LLC
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US83422E2046
CIK: 0001707502
CUSIP: 83422E105
Currency: USD
Full Time Employees: 121
Phone: 617 337 4680
Fiscal Year End: December
IPO Date: Jan 26, 2018
Description:

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Address:

500 Rutherford Avenue, Charlestown, MA, United States, 02129

People

Directors & Officers

Name Title Year Born
Mr. Ian F. Smith A.C.A., C.P.A. Executive Chair 1966
Mr. Alexander G. Cumbo President, CEO & Director 1971
Mr. Ilan Ganot Co-founder, Strategic Advisor to the CEO & Director 1974
Mr. David Tyronne Howton Jr., J.D. COO & Secretary 1972
Dr. Gabriel Brooks M.D. Chief Medical Officer 1977
Ms. Annie Ganot Co-Founder & VP of Patient Advocacy NA
Mr. Kevin Tan C.F.A. CFO & Treasurer 1978
Mr. Paul Herzich Chief Technology Officer 1978
Ms. Nicole Anderson Senior Director of Investor Relations & Corporate Communications NA
Dr. Jessie Hanrahan Ph.D. Chief Regulatory & Preclinical Operations Officer 1976

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 18, 2026 David T Howton N/A Sale 7.47K $5.82 $43.47K
Feb 18, 2026 Ilan Ganot N/A Sale 2.66K $5.82 $15.47K
Feb 18, 2026 Jessie Hanrahan N/A Sale 4.13K $5.82 $24.06K
Feb 18, 2026 Kevin Tan N/A Sale 5.40K $5.82 $31.45K
Feb 18, 2026 Paul Herzich N/A Sale 3.62K $5.82 $21.05K
Feb 18, 2026 Alexander Cumbo N/A Sale 16.64K $5.82 $96.87K
Feb 04, 2026 Ilan Ganot N/A Sale 7.21K $6.44 $46.40K
Feb 04, 2026 Paul Herzich N/A Sale 10.91K $6.44 $70.23K
Feb 04, 2026 Kevin Tan N/A Sale 14.78K $6.44 $95.20K
Feb 04, 2026 Jessie Hanrahan N/A Sale 12.35K $6.44 $79.52K
Feb 04, 2026 Gabriel Brooks N/A Sale 12.62K $6.44 $81.25K
Feb 04, 2026 David T Howton N/A Sale 18.89K $6.44 $121.68K
Feb 04, 2026 Alexander Cumbo N/A Sale 48.91K $6.44 $315.00K
Feb 02, 2026 David T Howton N/A Sale 37.77K $6.44 $243.25K
Feb 02, 2026 Paul Herzich N/A Sale 26.25K $6.44 $169.05K
Feb 02, 2026 Paul Herzich N/A Sale 26.25K $6.44 $169.05K
Feb 02, 2026 Kevin Tan N/A Sale 26.84K $6.44 $172.83K
Feb 02, 2026 Jessie Hanrahan N/A Sale 26.54K $6.44 $170.89K
Feb 02, 2026 Jessie Hanrahan N/A Sale 26.54K $6.44 $170.89K
Feb 02, 2026 Gabriel Brooks N/A Sale 28.34K $6.44 $182.48K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Perceptive Advisors LLC 11.91M Mar 31, 2026 12.09% $1.68 0.62%
Bain Capital Life Sciences Investors, LLC 9.81M Mar 31, 2026 9.96% $6.37 23.98%
RA Capital Management, LLC 9.34M Mar 31, 2026 9.49% $0.71 60.72%
Siren, L.L.C. 7.69M Mar 31, 2026 7.81% $1.53 0.00%
Vestal Point Capital LP 5.00M Mar 31, 2026 5.08% $1.01 -14.02%
BlackRock Inc 4.96M Mar 31, 2026 5.04% $0.00 1.82%
HHG PLC 4.01M Mar 31, 2026 4.07% $0.01 0.00%
FMR Inc 3.61M Mar 31, 2026 3.66% $0.00 77.66%
Deep Track Capital, LP 3.57M Mar 31, 2026 3.62% $0.42 0.00%
Vanguard Group Inc 3.45M Dec 31, 2025 3.51% $0.00 12.03%
Armistice Capital, LLC 3.20M Mar 31, 2026 3.25% $0.41 22.51%
Vanguard Capital Management, LLC 2.67M Mar 31, 2026 2.72% $0.00 0.00%
Citadel Advisors Llc 2.60M Mar 31, 2026 2.64% $0.00 -2.52%
Ameriprise Financial Inc 2.44M Mar 31, 2026 2.48% $0.00 0.00%
Alyeska Investment Group, L.P. 2.28M Mar 31, 2026 2.32% $0.05 35.50%
Franklin Resources Inc 2.19M Mar 31, 2026 2.23% $0.00 37.12%
Point72 Asset Management, L.P. 2.05M Mar 31, 2026 2.08% $0.02 -15.12%
Redmile Group, LLC 2.01M Mar 31, 2026 2.04% $0.96 8.13%
Adage Capital Partners Gp LLC 1.76M Mar 31, 2026 1.78% $0.02 25.46%
Monashee Investment Management LLC 1.42M Mar 31, 2026 1.44% $5.56 5.22%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 3.15M 3.20% ▲ 51.33% Jun 30, 2026
2 Fidelity Select Biotechnology 2.61M 2.65% ▲ 0.00% May 31, 2026
3 State Street® SPDR® S&P® Biotech ETF 2.57M 2.61% ▼ 2.18% Jun 30, 2026
4 Franklin Biotechnology Discv A(acc)USD 2.19M 2.22% ▲ 0.00% Jun 30, 2026
5 iShares Russell 2000 ETF 2.07M 2.10% ▲ 0.60% Jun 30, 2026
6 Columbia Small Cap Growth 1.76M 1.79% ▲ 19.25% Jun 30, 2026
7 Columbia Small Cap Growth Inst 1.48M 1.50% ▲ 0.00% May 31, 2026
8 Franklin Biotechnology Discovery A 1.25M 1.27% ▲ 0.00% Jun 30, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 773.75K 0.79% ▲ 46.56% Jun 30, 2026
10 Fidelity Advisor Biotechnology I 677.57K 0.69% ▲ 0.00% May 31, 2026

Financial Highlights

Market Cap: $776.77M
EBITDA: $-194.84M
Book Value: $3.80
Earnings/Share: $-1.92
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -32.03%
ROE (TTM): -57.37%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Valuation Metrics

Enterprise Value: $409.86M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 98.45M
Shares Float: 51.04M
% Insiders: 73.60%
% Institutions: 10,473.80%
Short % Float: 20.65%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.64M
Gross Profit
subtotal
$-1.64M
SG&A
adjust
$-38.88M
R&D
adjust
$-140.33M
Operating Income
subtotal
$-179.21M
Other / Non-Operating Items
adjust
$4.88M
Net Income
subtotal
$-174.33M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SLDB.US!